vs

Side-by-side financial comparison of LandBridge Co LLC (LB) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

LandBridge Co LLC is the larger business by last-quarter revenue ($56.8M vs $44.6M, roughly 1.3× PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). LandBridge Co LLC runs the higher net margin — 14.2% vs -90.4%, a 104.6% gap on every dollar of revenue. On growth, LandBridge Co LLC posted the faster year-over-year revenue change (55.6% vs 13.8%). LandBridge Co LLC produced more free cash flow last quarter ($122.0M vs $-19.9M). Over the past eight quarters, LandBridge Co LLC's revenue compounded faster (72.8% CAGR vs 7.3%).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

LB vs PACB — Head-to-Head

Bigger by revenue
LB
LB
1.3× larger
LB
$56.8M
$44.6M
PACB
Growing faster (revenue YoY)
LB
LB
+41.7% gap
LB
55.6%
13.8%
PACB
Higher net margin
LB
LB
104.6% more per $
LB
14.2%
-90.4%
PACB
More free cash flow
LB
LB
$142.0M more FCF
LB
$122.0M
$-19.9M
PACB
Faster 2-yr revenue CAGR
LB
LB
Annualised
LB
72.8%
7.3%
PACB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LB
LB
PACB
PACB
Revenue
$56.8M
$44.6M
Net Profit
$8.1M
$-40.4M
Gross Margin
37.1%
Operating Margin
60.0%
-92.3%
Net Margin
14.2%
-90.4%
Revenue YoY
55.6%
13.8%
Net Profit YoY
-83.7%
-1802.7%
EPS (diluted)
$0.24
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LB
LB
PACB
PACB
Q4 25
$56.8M
$44.6M
Q3 25
$50.8M
$38.4M
Q2 25
$47.5M
$39.8M
Q1 25
$44.0M
$37.2M
Q4 24
$36.5M
$39.2M
Q3 24
$28.5M
$40.0M
Q2 24
$26.0M
$36.0M
Q1 24
$19.0M
$38.8M
Net Profit
LB
LB
PACB
PACB
Q4 25
$8.1M
$-40.4M
Q3 25
$8.1M
$-38.0M
Q2 25
$7.5M
$-41.9M
Q1 25
$6.5M
$-426.1M
Q4 24
$49.3M
$2.4M
Q3 24
$2.7M
$-60.7M
Q2 24
$-57.7M
$-173.3M
Q1 24
$10.8M
$-78.2M
Gross Margin
LB
LB
PACB
PACB
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Q1 24
29.1%
Operating Margin
LB
LB
PACB
PACB
Q4 25
60.0%
-92.3%
Q3 25
60.8%
-101.1%
Q2 25
60.0%
-112.8%
Q1 25
57.0%
-1154.5%
Q4 24
49.4%
-390.1%
Q3 24
11.2%
-160.3%
Q2 24
-197.4%
-488.3%
Q1 24
71.1%
-209.6%
Net Margin
LB
LB
PACB
PACB
Q4 25
14.2%
-90.4%
Q3 25
15.9%
-98.9%
Q2 25
15.8%
-105.4%
Q1 25
14.7%
-1146.8%
Q4 24
135.2%
6.0%
Q3 24
9.3%
-151.9%
Q2 24
-222.1%
-481.3%
Q1 24
56.7%
-201.4%
EPS (diluted)
LB
LB
PACB
PACB
Q4 25
$0.24
$-0.11
Q3 25
$0.26
$-0.13
Q2 25
$0.24
$-0.14
Q1 25
$0.20
$-1.44
Q4 24
$-0.44
Q3 24
$-0.04
$-0.22
Q2 24
$-0.64
Q1 24
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LB
LB
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$30.7M
$279.5M
Total DebtLower is stronger
$570.7M
Stockholders' EquityBook value
$340.3M
$5.3M
Total Assets
$1.4B
$784.1M
Debt / EquityLower = less leverage
1.68×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LB
LB
PACB
PACB
Q4 25
$30.7M
$279.5M
Q3 25
$28.3M
$298.7M
Q2 25
$20.3M
$314.7M
Q1 25
$14.9M
$343.1M
Q4 24
$37.0M
$389.9M
Q3 24
$14.4M
$471.1M
Q2 24
$24.6M
$509.8M
Q1 24
$561.9M
Total Debt
LB
LB
PACB
PACB
Q4 25
$570.7M
Q3 25
$366.1M
Q2 25
$370.9M
Q1 25
$375.5M
Q4 24
$385.5M
Q3 24
$242.4M
Q2 24
$360.8M
Q1 24
Stockholders' Equity
LB
LB
PACB
PACB
Q4 25
$340.3M
$5.3M
Q3 25
$272.0M
$36.1M
Q2 25
$266.4M
$61.5M
Q1 25
$217.0M
$91.6M
Q4 24
$211.8M
$506.6M
Q3 24
$97.2M
$453.1M
Q2 24
$296.4M
$492.7M
Q1 24
$162.3M
$649.0M
Total Assets
LB
LB
PACB
PACB
Q4 25
$1.4B
$784.1M
Q3 25
$1.1B
$803.2M
Q2 25
$1.1B
$825.5M
Q1 25
$1.0B
$860.8M
Q4 24
$1.0B
$1.3B
Q3 24
$689.9M
$1.5B
Q2 24
$710.5M
$1.5B
Q1 24
$1.7B
Debt / Equity
LB
LB
PACB
PACB
Q4 25
1.68×
Q3 25
1.35×
Q2 25
1.39×
Q1 25
1.73×
Q4 24
1.82×
Q3 24
2.49×
Q2 24
1.22×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LB
LB
PACB
PACB
Operating Cash FlowLast quarter
$126.3M
$-19.1M
Free Cash FlowOCF − Capex
$122.0M
$-19.9M
FCF MarginFCF / Revenue
214.9%
-44.6%
Capex IntensityCapex / Revenue
7.5%
1.9%
Cash ConversionOCF / Net Profit
15.68×
TTM Free Cash FlowTrailing 4 quarters
$207.7M
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LB
LB
PACB
PACB
Q4 25
$126.3M
$-19.1M
Q3 25
$34.9M
$-18.7M
Q2 25
$37.3M
$-29.4M
Q1 25
$15.9M
$-44.1M
Q4 24
$67.6M
$-30.6M
Q3 24
$7.5M
$-45.5M
Q2 24
$16.0M
$-54.3M
Q1 24
$17.2M
$-75.7M
Free Cash Flow
LB
LB
PACB
PACB
Q4 25
$122.0M
$-19.9M
Q3 25
$33.7M
$-18.8M
Q2 25
$36.1M
$-29.9M
Q1 25
$15.8M
$-45.4M
Q4 24
$66.7M
$-32.3M
Q3 24
$7.1M
$-46.3M
Q2 24
$15.7M
$-55.7M
Q1 24
$17.1M
$-79.6M
FCF Margin
LB
LB
PACB
PACB
Q4 25
214.9%
-44.6%
Q3 25
66.3%
-48.9%
Q2 25
75.9%
-75.3%
Q1 25
36.0%
-122.3%
Q4 24
182.6%
-82.3%
Q3 24
25.1%
-115.7%
Q2 24
60.4%
-154.8%
Q1 24
90.1%
-205.0%
Capex Intensity
LB
LB
PACB
PACB
Q4 25
7.5%
1.9%
Q3 25
2.3%
0.2%
Q2 25
2.6%
1.4%
Q1 25
0.2%
3.7%
Q4 24
2.7%
4.1%
Q3 24
1.1%
2.0%
Q2 24
1.4%
4.1%
Q1 24
0.5%
10.0%
Cash Conversion
LB
LB
PACB
PACB
Q4 25
15.68×
Q3 25
4.31×
Q2 25
4.98×
Q1 25
2.46×
Q4 24
1.37×
-12.93×
Q3 24
2.80×
Q2 24
Q1 24
1.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LB
LB

Segment breakdown not available.

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons